WO2009038026A1 - Ｃｔｌ誘導剤組成物 - Google Patents

Ｃｔｌ誘導剤組成物 Download PDF

Info

Publication number
WO2009038026A1
WO2009038026A1 PCT/JP2008/066589 JP2008066589W WO2009038026A1 WO 2009038026 A1 WO2009038026 A1 WO 2009038026A1 JP 2008066589 W JP2008066589 W JP 2008066589W WO 2009038026 A1 WO2009038026 A1 WO 2009038026A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
hla
positive patients
ctl inducer
inducer composition
Prior art date
Application number
PCT/JP2008/066589
Other languages
English (en)
French (fr)
Inventor
Kyogo Itoh
Shigeki Shichijo
Akira Yamada
Original Assignee
Kurume University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020127009983A priority Critical patent/KR101512885B1/ko
Priority to EP08832117A priority patent/EP2196209A4/en
Priority to CN200880108352.1A priority patent/CN101854945B/zh
Priority to JP2009533124A priority patent/JP5568309B2/ja
Application filed by Kurume University filed Critical Kurume University
Priority to KR1020107005386A priority patent/KR101294514B1/ko
Priority to CN202210146372.XA priority patent/CN114617954A/zh
Priority to EP16194948.2A priority patent/EP3156061B1/en
Priority to EP18205301.7A priority patent/EP3494981A1/en
Priority to KR1020147025893A priority patent/KR101547788B1/ko
Priority to KR1020147006414A priority patent/KR101479455B1/ko
Priority to US12/733,686 priority patent/US9102715B2/en
Priority to CA2697896A priority patent/CA2697896C/en
Publication of WO2009038026A1 publication Critical patent/WO2009038026A1/ja
Priority to US14/789,139 priority patent/US9642900B2/en
Priority to US15/474,165 priority patent/US20170202913A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　配列表の配列番号１乃至２７からなる群から選択される１以上のペプチドを含み、HLA-A2陽性患者群、HLA-A24陽性患者群、HLA-A26陽性患者群およびHLA-A3スーパータイプ陽性患者群からなる群から選択される２以上の患者群において癌またはＣ型肝炎ウイルス関連疾患の処置または予防のために用いうる、ＣＴＬ誘導剤組成物を提供する。
PCT/JP2008/066589 2007-09-18 2008-09-12 Ｃｔｌ誘導剤組成物 WO2009038026A1 (ja)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN202210146372.XA CN114617954A (zh) 2007-09-18 2008-09-12 Ctl诱导剂组合物
CN200880108352.1A CN101854945B (zh) 2007-09-18 2008-09-12 Ctl诱导剂组合物
JP2009533124A JP5568309B2 (ja) 2007-09-18 2008-09-12 Ｃｔｌ誘導剤組成物
EP18205301.7A EP3494981A1 (en) 2007-09-18 2008-09-12 Ctl inducer composition
KR1020107005386A KR101294514B1 (ko) 2007-09-18 2008-09-12 Ｃｔｌ 유도제 조성물
EP08832117A EP2196209A4 (en) 2007-09-18 2008-09-12 INDUCTIVE COMPOSITION OF CYTOTOXIC T LYMPHOCYTES
EP16194948.2A EP3156061B1 (en) 2007-09-18 2008-09-12 Ctl inducer composition
KR1020127009983A KR101512885B1 (ko) 2007-09-18 2008-09-12 Ｃｔｌ 유도제 조성물
KR1020147025893A KR101547788B1 (ko) 2007-09-18 2008-09-12 Ｃｔｌ 유도제 조성물
KR1020147006414A KR101479455B1 (ko) 2007-09-18 2008-09-12 Ｃｔｌ 유도제 조성물
US12/733,686 US9102715B2 (en) 2007-09-18 2008-09-12 CTL inducer composition
CA2697896A CA2697896C (en) 2007-09-18 2008-09-12 Ctl inducer composition
US14/789,139 US9642900B2 (en) 2007-09-18 2015-07-01 CTL inducer composition
US15/474,165 US20170202913A1 (en) 2007-09-18 2017-03-30 Ctl inducer composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-241161 2007-09-18
JP2007241161 2007-09-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/733,686 A-371-Of-International US9102715B2 (en) 2007-09-18 2008-09-12 CTL inducer composition
US14/789,139 Division US9642900B2 (en) 2007-09-18 2015-07-01 CTL inducer composition

Publications (1)

Publication Number Publication Date
WO2009038026A1 true WO2009038026A1 (ja) 2009-03-26

Family

ID=40467842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066589 WO2009038026A1 (ja) 2007-09-18 2008-09-12 Ｃｔｌ誘導剤組成物

Country Status (8)

Country Link
US (3) US9102715B2 (ja)
EP (4) EP2196209A4 (ja)
JP (1) JP5568309B2 (ja)
KR (4) KR101512885B1 (ja)
CN (4) CN101854945B (ja)
CA (2) CA2697896C (ja)
ES (2) ES2714200T3 (ja)
WO (1) WO2009038026A1 (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005161A1 (ja) 2010-07-07 2012-01-12 株式会社グリーンペプタイド がんペプチドワクチン
WO2014136814A1 (ja) * 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
WO2014162962A1 (ja) * 2013-04-01 2014-10-09 学校法人 久留米大学 腫瘍抗原ペプチド
WO2014181805A1 (ja) * 2013-05-09 2014-11-13 学校法人 久留米大学 ペプチドカクテルワクチン
JPWO2012176879A1 (ja) * 2011-06-24 2015-02-23 学校法人 久留米大学 がんの検査用試薬及び検査方法
CN104379595A (zh) * 2012-06-25 2015-02-25 Hoya株式会社 Egfr结合肽
US9102715B2 (en) 2007-09-18 2015-08-11 Green Peptide Co., Ltd. CTL inducer composition
US10137183B2 (en) 2013-10-21 2018-11-27 Taiho Pharmaceutical Co., Ltd. Peptide compositions having 4 linked CTL epitopes and uses thereof
JP2021523946A (ja) * 2018-05-15 2021-09-09 インテルク ペプチド セラピューティクス リミテッド ペプチド活性化剤
JP2021523945A (ja) * 2018-05-15 2021-09-09 インテルク ペプチド セラピューティクス リミテッド 活性化剤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111848732B (zh) * 2019-04-30 2024-03-12 上海细胞治疗集团有限公司 多肽组合物及疫苗
CN111848733B (zh) * 2019-04-30 2024-03-12 上海细胞治疗集团有限公司 一种多肽组合物及疫苗

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3519215A1 (de) * 1985-04-13 1986-10-16 Ziegler, Horst, Prof. Dr., 4790 Paderborn Fuehler, insbesondere zur verwendung an einem fluegelraddurchflussmesser
JP4138073B2 (ja) 1998-05-08 2008-08-20 株式会社グリーンペプタイド ヒト癌退縮抗原タンパク質
ATE375362T1 (de) 1998-06-25 2007-10-15 Kyogo Itoh Von cyclophilin b abstammende tumorantigen- peptide
NZ510154A (en) * 1998-08-28 2002-11-26 Sumitomo Pharma A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
ATE464383T1 (de) * 1999-08-05 2010-04-15 Greenpeptide Co Ltd Tumor antigen
WO2002010369A1 (fr) 2000-07-31 2002-02-07 Kyogo Itoh Antigene associe aux tumeurs
JP4097178B2 (ja) 2000-10-03 2008-06-11 株式会社グリーンペプタイド 腫瘍抗原
KR100669065B1 (ko) * 2001-04-03 2007-01-15 다카라 바이오 가부시키가이샤 세포상해성 ｔ 림프구
WO2003025569A1 (fr) 2001-09-18 2003-03-27 Kyogo Itoh Procede de detection de l'immunite cellulaire et son application sur des medicaments
WO2003050140A1 (fr) 2001-12-10 2003-06-19 Kyogo Itoh Antigenes tumoraux
JP2004000216A (ja) 2002-04-26 2004-01-08 Kyogo Ito 腫瘍抗原
JP2006096663A (ja) * 2002-10-17 2006-04-13 Sangaku Renkei Kiko Kyushu:Kk 癌遺伝子ワクチン
JP3960614B2 (ja) 2003-08-31 2007-08-15 株式会社イムノディア 抗ペプチド抗体測定法とペプチドワクチンのワクチン候補選択方法
US20080254445A1 (en) 2003-09-22 2008-10-16 Kyogo Itoh Prognosis in Cancer Patients Vaccinated with a Cancer Antigen Peptide-Associated Agent
WO2005041981A1 (en) 2003-10-31 2005-05-12 Kurume University Combination therapy of peptide vaccination and estramustine treatment
KR20130062368A (ko) * 2003-11-05 2013-06-12 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드
JP4443202B2 (ja) 2003-12-03 2010-03-31 株式会社グリーンペプタイド Ｃｄ４陽性ｔ細胞に認識されるペプチド
JP4579581B2 (ja) 2003-12-08 2010-11-10 株式会社グリーンペプタイド 副甲状腺ホルモン関連タンパク質のｈｌａ−ａ２４またはｈｌａ−ａ２結合ペプチド
JP2005170799A (ja) 2003-12-08 2005-06-30 Univ Kurume ｚｅｓｔｅホモログ２のエンハンサーのＨＬＡ−Ａ２４結合ペプチド
CA2554195C (en) * 2004-01-23 2011-02-22 Green Peptide Co., Ltd. Peptide originating in epidermal growth factor receptor (egfr)
JP4925033B2 (ja) 2004-02-03 2012-04-25 学校法人 久留米大学 ストレス誘導抗アポトーシス分子（ｉｅｘ−１）由来ペプチド
JPWO2005083074A1 (ja) 2004-03-01 2007-11-22 有限会社金沢大学ティ・エル・オー 腫瘍抗原ペプチド
US20080014186A1 (en) 2004-05-26 2008-01-17 Green Peptide Co., Ltd. Hla-A24 or Hla-A2 Binding Peptides of Parathyroid Hormone-Related Protein
WO2005123122A1 (ja) 2004-06-21 2005-12-29 Green Peptide Co., Ltd. 癌治療ペプチドワクチン
US20100184699A1 (en) * 2005-06-29 2010-07-22 Kyogo Itoh Peptide Derived From Prostate-Related Protein As Cancer Vaccine Candidate For Prostate Cancer Patient Who Is Positive For Hla-A3 Super-Type Allele Molecule
JP2009018990A (ja) 2005-10-25 2009-01-29 Univ Kurume Ｃ型肝炎ウイルス由来ペプチド
JP2007127179A (ja) 2005-11-02 2007-05-24 Denso Corp 粉体輸送配管の詰り防止構造
JPWO2007083763A1 (ja) * 2006-01-23 2009-06-11 株式会社グリーンペプタイド 生理活性ペプチドのエマルション製剤の調製方法、および当該製剤を調製するためのキット
US20100292138A1 (en) 2006-01-23 2010-11-18 Green Peptide Co., Ltd. Peptide Derived from Hepatitis C Virus
JP2007212179A (ja) 2006-02-07 2007-08-23 Nsk Ltd 転がり軸受の特性測定用支持装置と転がり軸受の特性測定装置
JP5114403B2 (ja) 2006-07-11 2013-01-09 株式会社グリーンペプタイド Ｈｌａ−ａ３スーパータイプアレル陽性前立腺癌患者に対する癌ワクチン療法に有用なｓａｒｔ３由来ペプチド
WO2009022652A1 (ja) 2007-08-16 2009-02-19 Kurume University HLA-A3スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なLck由来ペプチド
EP2196209A4 (en) 2007-09-18 2010-11-24 Greenpeptide Co Ltd INDUCTIVE COMPOSITION OF CYTOTOXIC T LYMPHOCYTES
WO2010050181A1 (ja) 2008-10-27 2010-05-06 株式会社グリーンペプタイド Ｃ型肝炎ウイルスによる肝癌の発症および再発予防ワクチン

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
MATSUEDA S. ET AL: "Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles", CLINICAL CANCER RESEARCH, vol. 11, no. 19, 1 October 2005 (2005-10-01), pages 6933 - 6943, XP003004983 *
NOBUKAZU KOMATSU ET AL: "Shushu no HLA class I Bunshi ni Ketsugo Kano na HCV Yurai Peptide ni yoru Peptide Vaccine no Kanosei", 25 May 2007, SOCIETY FOR FUNDAMENTAL CANCER IMMUNOLOGY, SOKAI SHOROKUSHU, pages: 69, XP008127610 *
SASADA T. ET AL: "Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients", CANCER RESEARCH, vol. 64, no. 8, 15 April 2004 (2004-04-15), pages 2882 - 2888, XP002989506 *
See also references of EP2196209A4 *
TAKAFUMI MINAMI ET AL: "HLA-A3 Yosei Zenritsusengan Kanja ni Taisuru SART3 Yurai Peptide Vaccine no Kaihatsu", THE JAPANESE JOURNAL OF UROLOGY, vol. 98, no. 2, 20 February 2007 (2007-02-20), pages 475, XP008127609 *
TAKASHI MINE: "Gan Vaccine Ryoho no Genjo to Tenbo 4. Tailor-made Peptide Vaccine", SURGERY FRONTIER, vol. 13, no. 3, 1 September 2006 (2006-09-01), pages 249 - 254, XP008127611 *
TAKEDATSU H. ET AL: "Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients", CLINICAL CANCER RESEARCH, vol. 10, no. 3, 1 February 2004 (2004-02-01), pages 1112 - 1120, XP003004980 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102715B2 (en) 2007-09-18 2015-08-11 Green Peptide Co., Ltd. CTL inducer composition
US9642900B2 (en) 2007-09-18 2017-05-09 Green Peptide Co., Ltd. CTL inducer composition
WO2012005161A1 (ja) 2010-07-07 2012-01-12 株式会社グリーンペプタイド がんペプチドワクチン
JP5706895B2 (ja) * 2010-07-07 2015-04-22 株式会社グリーンペプタイド がんペプチドワクチン
JP2015078227A (ja) * 2010-07-07 2015-04-23 株式会社グリーンペプタイド がんペプチドワクチン
US20150216958A1 (en) * 2010-07-07 2015-08-06 Green Peptide Co., Ltd. Cancer peptide vaccine
JPWO2012176879A1 (ja) * 2011-06-24 2015-02-23 学校法人 久留米大学 がんの検査用試薬及び検査方法
US9822148B2 (en) 2012-06-25 2017-11-21 Hoya Corporation EGFR-binding peptide
CN104379595A (zh) * 2012-06-25 2015-02-25 Hoya株式会社 Egfr结合肽
AU2014227019B2 (en) * 2013-03-08 2016-10-27 Taiho Pharmaceutical Co., Ltd. Novel peptide having 5 linked CTL epitopes
JP6077641B2 (ja) * 2013-03-08 2017-02-08 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
US9701729B2 (en) 2013-03-08 2017-07-11 Taiho Pharmaceutical Co., Ltd. Peptide having 5 linked CTL epitopes
WO2014136814A1 (ja) * 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
JPWO2014162962A1 (ja) * 2013-04-01 2017-02-16 学校法人 久留米大学 腫瘍抗原ペプチド
WO2014162962A1 (ja) * 2013-04-01 2014-10-09 学校法人 久留米大学 腫瘍抗原ペプチド
WO2014181805A1 (ja) * 2013-05-09 2014-11-13 学校法人 久留米大学 ペプチドカクテルワクチン
JPWO2014181805A1 (ja) * 2013-05-09 2017-02-23 株式会社グリーンペプタイド ペプチドカクテルワクチン
US10137183B2 (en) 2013-10-21 2018-11-27 Taiho Pharmaceutical Co., Ltd. Peptide compositions having 4 linked CTL epitopes and uses thereof
JP2021523946A (ja) * 2018-05-15 2021-09-09 インテルク ペプチド セラピューティクス リミテッド ペプチド活性化剤
JP2021523945A (ja) * 2018-05-15 2021-09-09 インテルク ペプチド セラピューティクス リミテッド 活性化剤
JP7386852B2 (ja) 2018-05-15 2023-11-27 インテルク ペプチド セラピューティクス リミテッド ペプチド活性化剤

Also Published As

Publication number Publication date
EP3494981A1 (en) 2019-06-12
KR101294514B1 (ko) 2013-08-12
JP5568309B2 (ja) 2014-08-06
CN114617954A (zh) 2022-06-14
CN108478780B (zh) 2022-01-18
KR20120065417A (ko) 2012-06-20
US9102715B2 (en) 2015-08-11
US9642900B2 (en) 2017-05-09
EP2196209A1 (en) 2010-06-16
CN101854945B (zh) 2015-07-01
KR101512885B1 (ko) 2015-04-16
US20170202913A1 (en) 2017-07-20
CA2697896C (en) 2016-06-28
KR101547788B1 (ko) 2015-08-26
US20150343041A1 (en) 2015-12-03
US20100278851A1 (en) 2010-11-04
ES2624879T3 (es) 2017-07-17
EP2801367A1 (en) 2014-11-12
CN108478780A (zh) 2018-09-04
EP3156061B1 (en) 2019-02-20
EP3156061A1 (en) 2017-04-19
KR20100047894A (ko) 2010-05-10
ES2714200T3 (es) 2019-05-27
KR101479455B1 (ko) 2015-01-05
EP2801367B1 (en) 2017-04-19
CN101854945A (zh) 2010-10-06
JPWO2009038026A1 (ja) 2011-01-06
CA2927770A1 (en) 2009-03-26
CN104922650A (zh) 2015-09-23
KR20140117699A (ko) 2014-10-07
CN104922650B (zh) 2018-04-24
CA2697896A1 (en) 2009-03-26
KR20140041938A (ko) 2014-04-04
CA2927770C (en) 2017-09-19
EP2196209A4 (en) 2010-11-24

Similar Documents

Publication Publication Date Title
WO2009038026A1 (ja) Ｃｔｌ誘導剤組成物
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ595063A (en) Polypeptides from neisseria meningitidis
EP2573110A3 (en) Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens
WO2007009894A3 (en) Peptides for use in the treatment of obesity
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
JP2013543497A5 (ja)
WO2009025196A1 (ja) Foxm1ペプチドおよびこれを含む薬剤
WO2007105111A3 (en) Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
RU2016113055A (ru) Композиция для лечения и профилактики доброкачественной гиперплазии простаты
PE20120425A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
NZ601345A (en) Combination adjuvant formulation
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
NZ624873A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
NZ599670A (en) Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
WO2008156914A3 (en) Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
WO2008129422A8 (en) Demannosylated recombinant factor viii for the treatment of patients with haemophilia a
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2005068632A8 (ja) ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2009022652A1 (ja) HLA-A3スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なLck由来ペプチド
WO2008113770A3 (en) Anti-androgen peptides and uses thereof in cancer therapy
WO2009066462A1 (ja) 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
WO2009072555A1 (ja) 癌ワクチン

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880108352.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08832117

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2697896

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20107005386

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009533124

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008832117

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12733686

Country of ref document: US